Jennifer R. Riggs

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

Deborah S. Mortensen, Sophie Perrin-Ninkovic, Graziella Shevlin et al. · Journal of Medicinal Chemistry · 2015 · 72 citations · Full text

Drug Target, Kinase Inhibitors, Pharmacotherapy +16

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality

Philip P. Chamberlain, Laura Akullian D’Agostino, J. Michael Ellis et al. · ACS Medicinal Chemistry Letters · 2019 · 66 citations · Full text

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Jennifer R. Riggs, Mark A. Nagy, Jan Elsner et al. · Journal of Medicinal Chemistry · 2017 · 59 citations · Full text

Breast Oncology, Pharmaceutical Chemistry, Tumor Biology +18

A novel protecting group for hindered phenols

Marvin M. Hansen, Jennifer R. Riggs · Tetrahedron Letters · 1998 · 41 citations

Biology, Phenomics, Plant Defence Activator +2

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Dan Zhu, Shuichan Xu, Gordafaried Deyanat‐Yazdi et al. · Molecular Cancer Therapeutics · 2018 · 35 citations